Precision BioSciences (DTIL) AI Stock Analysis

• Market Cap: $51.45M
• Dividend Yield: N/A
• Average Volume (3M): 162.39K
• Price to Earnings (P/E): 2.4
• Beta (1Y): 1.11
• Revenue Growth: -11.11%
• EPS Growth: 79.74%
• Country: US
• Employees: 108
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -2.21
• Shares Outstanding: 11,088,234
• 10 Day Avg. Volume: 85,976
• 30 Day Avg. Volume: 162,393
• PEG Ratio: <0.01
• Price to Book (P/B): 0.89
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.85
• Enterprise Value/Market Cap: -0.51
• Enterprise Value/Revenue: -0.09
• Enterprise Value/Gross Profit: -0.55
• Enterprise Value/Ebitda: -0.67
• 1Y Price Target: $34.33
• Price Target Upside: 649.56% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 62 Neutral
• Price Target: $5.00 ▲( 9.17% Upside)

The overall stock score reflects the balance of promising revenue growth and strategic advancements in clinical programs against the backdrop of profitability and cash flow challenges. The attractive valuation and low debt levels provide a foundation for potential long-term growth, though significant improvements in cash management and profitability are necessary to enhance the stock's outlook.

Positive Factors

Clinical Progress

Two wholly-owned ARCUS-based programs progressing well, backed by momentum from partner-led clinical validation.

Market Potential

The company's strategy for PBGENE-DMD could address up to 60% of DMD cases, which is significantly higher than existing treatments.

Regulatory Approval

The FDA has cleared the IND application for PBGENE-HBV in chronic HBV, allowing for enrollment to begin in the U.S. sites.

Negative Factors

Adverse Events

The treatment with PBGENE-HBV caused mild adverse events, all Grades 1 or 2 and were transient in nature.

Safety Concerns

There is an expectation that future updates at higher doses with 2-3 administrations will have a greater degree of toxicity.

Precision BioSciences Business Overview & Revenue Model

Company Description

Precision BioSciences (DTIL) is a biotechnology company specializing in genome editing technologies. The company focuses on developing therapeutic products using its proprietary ARCUS genome editing platform, which is designed to precisely target and edit DNA. Precision BioSciences operates primarily in the healthcare and biotechnology sectors, working to address unmet medical needs in areas such as oncology and genetic diseases.

How the Company Makes Money

Precision BioSciences generates revenue through various channels, including partnerships and collaborations with other biotechnology and pharmaceutical companies. These partnerships often involve licensing agreements for the use of its ARCUS technology, leading to milestone payments and royalties. Additionally, the company aims to commercialize its own therapeutic products, which could provide revenue from product sales. Significant factors contributing to its earnings include successful development and commercialization of therapies, as well as strategic alliances that leverage its genome editing expertise.

Precision BioSciences Financial Statement Overview

Summary

Precision BioSciences shows promising revenue growth and improved operating performance, but profitability and cash flow management remain key challenges. The low debt levels provide financial stability, but the company needs to enhance its cash generation capabilities to sustain long-term growth.

Income Statement

Precision BioSciences has shown a significant improvement in revenue, with a year-over-year growth rate of approximately 41% from 2023 to 2024. However, profitability is a concern as the net profit margin remains low due to high operating expenses relative to revenue, resulting in a net income of only $7.1 million in 2024 from a loss of $61.3 million in 2023. The gross profit margin is relatively stable at 100%, indicating that the company is retaining its revenue at the gross level efficiently. EBIT and EBITDA margins are positive, reflecting improved operating performance.

Balance Sheet

The company has a strong equity base with a debt-to-equity ratio of approximately 0.02 in 2024, indicating low financial leverage. However, the return on equity is modest at about 12.7%, suggesting moderate profitability relative to shareholder investment. The equity ratio is approximately 41.4%, reflecting a balanced asset structure. Overall, the balance sheet presents a stable financial position with low debt.

Cash Flow

The cash flow statement indicates challenges in cash management, with a negative operating cash flow of $58.4 million in 2024. Despite an improvement in free cash flow from the previous year, the free cash flow to net income ratio is negative, highlighting inefficiencies in converting net income into free cash flow. The operating cash flow to net income ratio is also negative, indicating that cash outflows from operations exceed net income.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
51.14M	68.70M	48.73M	25.10M	115.53M	24.29M
	Gross Profit
47.96M	64.12M	40.47M	16.09M	115.53M	24.29M
	EBIT
-42.54M	-26.16M	-43.74M	-100.37M	-39.40M	-109.83M
	EBITDA
-17.63M	13.53M	-32.04M	-62.79M	-20.27M	-99.19M
	Net Income Common Stockholders
-21.99M	7.17M	-61.32M	-122.91M	-30.92M	-109.01M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
77.22M	86.31M	116.68M	189.58M	143.66M	89.80M
	Total Assets
124.41M	136.39M	159.78M	238.17M	211.50M	150.16M
	Total Debt
1.36M	30.05M	31.27M	27.04M	9.11M	10.52M
	Net Debt
-75.86M	-55.85M	-85.41M	-162.54M	-134.55M	-79.28M
	Total Liabilities
75.07M	80.00M	140.92M	177.74M	120.33M	105.73M
	Stockholders Equity
49.34M	56.39M	18.86M	60.43M	91.17M	44.42M
Cash Flow		Free Cash Flow
-58.74M	-58.70M	-86.39M	-49.07M	-16.66M	-92.42M
	Operating Cash Flow
-58.52M	-58.45M	-84.11M	-45.75M	-10.85M	-87.39M
	Investing Cash Flow
-503.00K	-215.00K	5.83M	-3.32M	-5.80M	-5.03M
	Financing Cash Flow
21.04M	50.45M	5.39M	94.98M	70.52M	1.33M

Precision BioSciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DTIL, the sentiment is Negative. The current price of 4.58 is below the 20-day moving average (MA) of 5.12, below the 50-day MA of 5.00, and below the 200-day MA of 6.65, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 41.84 is Neutral, neither overbought nor oversold. The STOCH value of 28.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DTIL.

Precision BioSciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	68 Neutral	$335.57M	4.30	-58.97%	―	23.81%	146.45%
DTIL	62 Neutral	$51.45M	2.40	-50.81%	―	-11.11%	79.74%
Sector *	53 Neutral	$5.14B	3.03	-43.89%	2.83%	16.75%	-0.06%
IKNA	41 Neutral	$55.50M	―	-30.49%	―	-100.00%	37.59%
BLUE	40 Underperform	$48.86M	―	-546.55%	―	127.51%	56.94%
ACRV	36 Underperform	$36.69M	―	-62.41%	―	―	10.84%
ACET	27 Underperform	$59.44M	―	-55.83%	―	―	59.75%

Precision BioSciences Corporate Events

Precision BioSciences Reports Q1 Results and Business Update

On May 15, 2025, Precision BioSciences reported its first quarter financial results and provided a business update, highlighting new clinical data for its ARCUS-based programs. The company announced progress in its ELIMINATE-B trial for PBGENE-HBV, a potential curative treatment for chronic Hepatitis B, which received Fast Track Designation from the FDA. Additionally, Precision is accelerating its PBGENE-DMD program for Duchenne’s Muscular Dystrophy, aiming to file an IND/CTA in 2025, with clinical data expected in 2026. The company plans to pause the development of PBGENE-3243 to focus resources on these programs.

The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Precision BioSciences Accelerates PBGENE-DMD Program for DMD

On May 14, 2025, Precision BioSciences announced the acceleration of its PBGENE-DMD program, a first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD), highlighting preclinical evidence at the ASGCT Annual Meeting. The program aims to address the significant unmet need for DMD treatments by restoring the body’s production of functional dystrophin protein, potentially offering a durable intervention for most patients. Precision plans to submit an IND and/or CTA in 2025, with clinical data expected in 2026, while pausing development of PBGENE-3243 to focus on advancing PBGENE-DMD and PBGENE-HBV through Phase 1 clinical results.

The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.